Johnson and Johnson (JNJ) |
148.53 -1.03 (-0.69%) 04-24 16:00 |
Open: | 148.14 |
High: | 148.99 |
Low: | 146.86 |
Volume: | 7,535,446 |
Market Cap: | 357,925(M) |
PE Ratio: | 19.99 |
Exchange: | New York Stock Exchange |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 159.14 |
Resistance 1: | 153.02 |
Pivot price: | 148.86 |
Support 1: | 143.13 |
Support 2: | 119.08 |
52w High: | 175.97 |
52w Low: | 143.13 |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
EPS | 7.430 |
Book Value | 28.570 |
PEG Ratio | 2.96 |
Gross Profit | 0.000 |
Profit Margin (%) | 47.37 |
Operating Margin (%) | 28.80 |
Return on Assets (ttm) | 0.0 |
Return on Equity (ttm) | 0.0 |
Mon, 22 Apr 2024
Johnson & Johnson: Legal Woes Are Detrimental But Not Fatal (NYSE:JNJ) - Seeking Alpha
Mon, 22 Apr 2024
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Sat, 20 Apr 2024
J&J, Kenvue Told to Pay $45 Million to Baby Powder User's Family - Bloomberg
Thu, 18 Apr 2024
J&J wins trial over Florida woman who claimed its baby powder caused her cancer - Reuters
Tue, 16 Apr 2024
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results - Business Wire
Tue, 16 Apr 2024
J&J's medical device sales fall short, cancer drugs seen growing - Reuters.com
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |